TEMPEST THERAPEUTICS INC (TPST) Stock Price & Overview
NASDAQ:TPST • US87978U2078
Current stock price
The current stock price of TPST is 2.05 USD. Today TPST is up by 29.75%. In the past month the price decreased by -10.48%. In the past year, price decreased by -67.04%.
TPST Key Statistics
- Market Cap
- 27.06M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -6.64
- Dividend Yield
- N/A
TPST Stock Performance
TPST Stock Chart
TPST Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to TPST. When comparing the yearly performance of all stocks, TPST is a bad performer in the overall market: 94.2% of all stocks are doing better.
TPST Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to TPST. The financial health of TPST is average, but there are quite some concerns on its profitability.
TPST Earnings
TPST Forecast & Estimates
7 analysts have analysed TPST and the average price target is 11.22 USD. This implies a price increase of 447.32% is expected in the next year compared to the current price of 2.05.
TPST Groups
Sector & Classification
TPST Financial Highlights
Over the last trailing twelve months TPST reported a non-GAAP Earnings per Share(EPS) of -6.64. The EPS increased by 65.95% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -210.49% | ||
| ROE | -568.14% | ||
| Debt/Equity | 0 |
TPST Ownership
TPST Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.01 | 375.559B | ||
| AMGN | AMGEN INC | 15.38 | 191.693B | ||
| GILD | GILEAD SCIENCES INC | 15.72 | 176.393B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.5 | 113.496B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.02 | 81.177B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 43.17 | 42.608B | ||
| INSM | INSMED INC | N/A | 34.4B | ||
| NTRA | NATERA INC | N/A | 28.771B | ||
| BIIB | BIOGEN INC | 10.76 | 25.993B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.14 | 25.192B | ||
| MRNA | MODERNA INC | N/A | 20.253B | ||
| INCY | INCYTE CORP | 12.54 | 19.296B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 19.068B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About TPST
Company Profile
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
Company Info
IPO: 2012-10-04
TEMPEST THERAPEUTICS INC
2000 Sierra Point Parkway, Suite 400
Brisbane California CALIFORNIA US
CEO: Louis Arcudi
Employees: 24
Phone: 13026587581
TEMPEST THERAPEUTICS INC / TPST FAQ
What does TPST do?
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company is headquartered in Brisbane California, California and currently employs 24 full-time employees. The company went IPO on 2012-10-04. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company’s second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.
What is the current price of TPST stock?
The current stock price of TPST is 2.05 USD. The price increased by 29.75% in the last trading session.
Does TPST stock pay dividends?
TPST does not pay a dividend.
What is the ChartMill rating of TEMPEST THERAPEUTICS INC stock?
TPST has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
Can you provide the sector and industry classification for TEMPEST THERAPEUTICS INC?
TEMPEST THERAPEUTICS INC (TPST) operates in the Health Care sector and the Biotechnology industry.
Can you provide the short interest for TPST stock?
The outstanding short interest for TEMPEST THERAPEUTICS INC (TPST) is 1.58% of its float.